(NASDAQ: ILMN) Illumina's forecast annual revenue growth rate of 5.5% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Illumina's revenue in 2026 is $4,493,000,000.On average, 23 Wall Street analysts forecast ILMN's revenue for 2026 to be $705,321,000,000, with the lowest ILMN revenue forecast at $668,930,000,000, and the highest ILMN revenue forecast at $733,558,000,000. On average, 23 Wall Street analysts forecast ILMN's revenue for 2027 to be $746,091,000,000, with the lowest ILMN revenue forecast at $699,583,000,000, and the highest ILMN revenue forecast at $796,827,000,000.
In 2028, ILMN is forecast to generate $798,790,000,000 in revenue, with the lowest revenue forecast at $735,370,000,000 and the highest revenue forecast at $888,031,000,000.